Tuesday, November 25, 2014

Breast Cancer Hormone Treatment: Tamoxifen, other SERMs, and Aromatase Inhibitors

Resources




Review Date: 11/08/2010
Reviewed By: Harvey Simon, MD, Editor-in-Chief, Associate Professor of Medicine, Harvard Medical School; Physician, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org)